[go: up one dir, main page]

FI964284L - Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito - Google Patents

Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito Download PDF

Info

Publication number
FI964284L
FI964284L FI964284A FI964284A FI964284L FI 964284 L FI964284 L FI 964284L FI 964284 A FI964284 A FI 964284A FI 964284 A FI964284 A FI 964284A FI 964284 L FI964284 L FI 964284L
Authority
FI
Finland
Prior art keywords
apolipoprotein
polymorphism
alzheimer
disease treatment
disease
Prior art date
Application number
FI964284A
Other languages
English (en)
Swedish (sv)
Other versions
FI964284A0 (fi
FI964284A7 (fi
Inventor
Judes Poirier
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of FI964284A0 publication Critical patent/FI964284A0/fi
Publication of FI964284L publication Critical patent/FI964284L/fi
Publication of FI964284A7 publication Critical patent/FI964284A7/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
FI964284A 1994-04-27 1995-04-26 Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito FI964284A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9408465A GB9408465D0 (en) 1994-04-27 1994-04-27 Apolipoprotein e polymorphism & treatment of alzheimer's disease
PCT/CA1995/000240 WO1995029257A2 (en) 1994-04-27 1995-04-26 Apolipoprotein e polymorphism and treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
FI964284A0 FI964284A0 (fi) 1996-10-24
FI964284L true FI964284L (fi) 1996-12-23
FI964284A7 FI964284A7 (fi) 1996-12-23

Family

ID=10754293

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964284A FI964284A7 (fi) 1994-04-27 1995-04-26 Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito

Country Status (13)

Country Link
US (1) US5935781A (fi)
EP (1) EP0804615B1 (fi)
JP (1) JP3285585B2 (fi)
AT (1) ATE247717T1 (fi)
AU (1) AU693193B2 (fi)
CA (1) CA2188933C (fi)
DE (1) DE69531557T2 (fi)
FI (1) FI964284A7 (fi)
GB (1) GB9408465D0 (fi)
MX (1) MX9605176A (fi)
NO (1) NO964543L (fi)
NZ (1) NZ284412A (fi)
WO (1) WO1995029257A2 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7049078B2 (en) * 1994-04-27 2006-05-23 Judés Poirier Apolipoprotein E polymorphism and treatment of alzheimer's disease
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5767337A (en) * 1995-07-31 1998-06-16 Duke University Creation of human apolipoprotein E isoform specific transgenic mice in apolipoprotein deficient "knockout" mice
GB9525481D0 (en) * 1995-12-13 1996-02-14 Royston M C Novel method
ES2115553B1 (es) * 1996-10-23 1999-02-16 Boehringer Ingelheim Espana Metodo para detectar la presencia de polimorfismos de dna, estuche de ensayo y acidos nucleicos recombinantes correspondientes.
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
WO1999015159A2 (en) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
ES2142248B1 (es) * 1997-11-20 2000-11-16 Univ Madrid Autonoma Polimorfismos en el promotor del gen humano de la apolipoproteina e, y sus usos para aplicaciones diagnosticas y terapeuticas.
US6251587B1 (en) 1997-12-16 2001-06-26 Nova Molecular, Inc. Method for determining the prognosis of a patient with a neurological disease
WO1999058640A2 (en) 1998-05-11 1999-11-18 Philadelphia Health And Education Corporation Mct-1, a human oncogene
AU773765B2 (en) * 1998-10-01 2004-06-03 Variagenics, Inc. Methods for treating or identifying a subject at risk for a neurological disease by determining the presence of variant GPIIIA and/or variant GPIIB allele
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
US6573049B1 (en) 1999-07-26 2003-06-03 Nuvelo, Inc. Genotyping of the paraoxonase 1 gene for prognosing, diagnosing, and treating a disease
US6432643B1 (en) * 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
EP1113081A1 (en) * 1999-12-28 2001-07-04 Institut Pasteur De Lille Implication of a known gene named CP2/LSF/LBP-1 in Alzheimer's disease
US6453244B1 (en) * 2000-02-10 2002-09-17 Stanford University Detection of polymorphisms by denaturing high-performance liquid chromatography
US20020019746A1 (en) * 2000-03-16 2002-02-14 Rienhoff Hugh Y. Aggregating persons with a select profile for further medical characterization
DE60138019D1 (de) * 2000-05-01 2009-04-30 Accera Inc Verwendung von triglyceriden mit mittellangen ketten zur behandlung und vorbeugung der alzheimerschen erkrankung
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US20020010552A1 (en) * 2000-05-26 2002-01-24 Hugh Rienhoff System for genetically characterizing an individual for evaluation using genetic and phenotypic variation over a wide area network
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040106124A1 (en) * 2001-02-12 2004-06-03 Murphy Greer M. Methods for improving the treatment of major depression by genotyping for the gene for apolipoproteine e4 and for improving the terapeutic response of humans having major depression and carrying the gene for apolipoprotein e4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20040005566A1 (en) * 2002-07-02 2004-01-08 Genelink, Inc. Kits and methods for assessing cardiovascular health
CA2573673A1 (en) 2004-07-16 2006-01-26 Proteosys Ag Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
DK2500017T3 (da) * 2006-04-03 2017-11-06 Accera Inc Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
US20080249103A1 (en) * 2006-11-15 2008-10-09 Sirtris Pharmaceuticals, Inc. Sirtuin polymorphisms and methods of use thereof
EP2650379B1 (en) 2007-07-31 2015-09-16 Accera, Inc. Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function
CA2729622C (en) * 2008-07-03 2017-07-25 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
US8105809B2 (en) * 2008-07-03 2012-01-31 Accera, Inc. Enzymatic synthesis of acetoacetate esters and derivatives
WO2010081823A1 (en) 2009-01-13 2010-07-22 Proteosys Ag Pirenzepine as otoprotective agent
US20110177061A1 (en) 2009-07-10 2011-07-21 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
EP3555629A4 (en) 2016-12-18 2020-11-25 Selonterra, Inc. USE OF APOE4 PATTERNED MEDIATION GENES FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
US5643960A (en) * 1994-04-15 1997-07-01 Duke University Method of delaying onset of alzheimer's disease symptoms
GB9408465D0 (en) * 1994-04-27 1994-06-22 Univ Mcgill Apolipoprotein e polymorphism & treatment of alzheimer's disease
GB9415073D0 (en) * 1994-06-27 1994-09-14 Smithkline Beecham Plc Novel method
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
GB9414624D0 (en) * 1994-07-20 1994-09-07 Smithkline Beecham Plc Novel method

Also Published As

Publication number Publication date
DE69531557T2 (de) 2004-06-17
MX9605176A (es) 1998-06-30
EP0804615B1 (en) 2003-08-20
WO1995029257A3 (en) 1995-11-23
CA2188933A1 (en) 1995-11-02
CA2188933C (en) 2000-11-14
WO1995029257A2 (en) 1995-11-02
JPH10500288A (ja) 1998-01-13
NO964543L (no) 1996-12-20
JP3285585B2 (ja) 2002-05-27
FI964284A0 (fi) 1996-10-24
NO964543D0 (no) 1996-10-25
NZ284412A (en) 2000-01-28
GB9408465D0 (en) 1994-06-22
EP0804615A1 (en) 1997-11-05
AU693193B2 (en) 1998-06-25
AU2300695A (en) 1995-11-16
ATE247717T1 (de) 2003-09-15
US5935781A (en) 1999-08-10
DE69531557D1 (de) 2003-09-25
FI964284A7 (fi) 1996-12-23

Similar Documents

Publication Publication Date Title
FI964284L (fi) Apolipoproteiini E:n polymorfismi ja Alzheimerin taudin hoito
CY2018020I1 (el) Θεραπεια της νοσου ρομρε
FI962557L (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
FI933946A7 (fi) Hypoglykeemisinä aineina ja Alzheimerin taudin hoidossa käyttökelpoisia yhdisteitä
FI964060A0 (fi) Kosketusjousi
FI951701A7 (fi) Menetelmät Alzheimerin taudin tunnistamiseksi
EP1007048A4 (en) IDENTIFICATION OF MEANS FOR TREATING ALZHEIMERISCHEN DISEASE
KR970704445A (ko) 페노티아진 및/또는 티옥산틴을 사용한 알츠하이머 병의 치료 및/또는 예방 방법(methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
FI953915A0 (fi) Dupuytrenin taudin lievittämiseen
NO20001869D0 (no) Fremgangsmõte for behandling av Alzheimerssykdom
BR9506419A (pt) Composiçao microbicida e processo de esterilizaçao
AU1189395A (en) Apolipoprotein e polymorphism and alzheimer's disease
BR9500163A (pt) Composição fungicida e processo de tratamento de culturas
ITRM940124V0 (it) "brandina o cuccia pieghegole e/o smontabile"
AU8700998A (en) Use of Apolipoprotein polymorphism E in the treatment of Alzheimer's disease
KR940022019U (ko) 남성물리치료기
KR960016090U (ko) 환자복
KR950031762U (ko) 브라케트의 효율적인 구조
ITTO940810A0 (it) "sedia"
KR950024858U (ko) 카리프트의 풋보드 확장장치
KR950024510U (ko) 운전자용 졸음 방지구
KR960001317U (ko) 카스테레오의 고정구조
KR960006682U (ko) 튜너의 폰잭핀
UA25492A (uk) Спосіб лікуваhhя хвороби гіршпруhга
KR960021496U (ko) 운전자의 발 지지대

Legal Events

Date Code Title Description
MA Patent expired